This second Phase II trial will investigate the product as an adjunct to systemic antibiotic therapy for treating moderately infected ulcers, as defined according to Infectious Disease Society of America guidelines. The third Phase II trial, planned to commence later in April, 2008, will investigate the product for the prevention of infection in diabetic foot ulcers.
Michael Myers, Innocoll’s president and CEO, said: “Since there are currently no topical antibiotics on the market for infected diabetic foot ulcers, we view this Phase II program as a significant step towards treating and potentially preventing this highly serious and widely prevalent complication of diabetes.”